A phase I study of irinotecan administered on a weekly schedule in pediatric patients

Pediatric Blood and Cancer

Volumn 46, Issue 1, 2006, Pages 50-55

  Bomgaars, L ^a,d   Kerr, J ^a   Berg, S ^a   Kuttesch, J ^b,c   Klenke, R ^a   Blaney, S M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^d TEXAS CHILDREN S CANCER CENTER   (United States)

Author keywords

Irinotecan; Pediatric oncology; Pharmacokinetic; Phase I

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; IRINOTECAN; ONDANSETRON;

ABDOMINAL CRAMP; ADOLESCENT; ADULT; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DIAPHORESIS; DIARRHEA; DRUG BLOOD LEVEL; EPENDYMOMA; EWING SARCOMA; FATIGUE; FEMALE; FEVER; FLUSHING; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCALCEMIA; HYPERSALIVATION; HYPOCALCEMIA; HYPOCAPNIA; HYPOCHLOREMIA; HYPOKALEMIA; INFECTION; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUROBLASTOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS;

EID: 28844496370     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20355     Document Type: Article

References (21)

1. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-2194.
2. Santos A, Zanetta S, Cresteil T, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000;6:2012-2020.
3. Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients: A Pediatric Oncology Group Study. Clin Cancer Res 2001;7:32-37.
4. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815-1824.
5. NCI: National Cancer Institute. Guidelines for reporting adverse drug reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, 1998.
6. Houghton PJ, Cheshire PJ, Hallman JD II, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
7. Houghton PJ, Cheshire PJ, Hallman JC, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)- carbonyloxy-camptothecin against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 1993;53:2823-2829.
8. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11: A new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992;10:16-20.
9. Verschraegen CF, Levy T, Kudelka AP, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997;15:625-631.
10. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
11. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
12. Murry D, Berg S, Stewart C, et al. Pharmacokinetics (PK) of irinotecan (CPT-11) in pediatric patients with refractory solid tumors: A Pediatric Oncology Group Study. Proc Am Assoc Cancer Research 1998;39:Abstract 3552.
13. Schaaf L, Ichhpurani N, Elfring O, et al. Influence of age on the pharmacokinetics of inrinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G), in patients with previously treated colorectal cancer. Proc Am Soc Clin Oncol 1997;16:202a.
14. Rothenberg ML, Kuhn JO, Burris HA III, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993;11:2194-2204.
15. Rothenberg ML, Eckardt JR, Kuhn JO, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128-1135.
16. Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusions of CPT-11: A new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991;83:1164-1168.
17. Vassal O, Santos A, Deroussent A, et al. Clinical pharmacology of irinotecan (CPT-11) in children. Proc Am Soc Clin Oncol 1998;17:187a.
18. Rivory LP, Haaz MC, Canal P, et al. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 1997;3:1261-1266.
19. Sparreboom A, de Jonge MJ, de Bruijn P, et al. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 1998;4:2747-2754.
20. Pilot HC, Goldberg RM, Reid JM, et al. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res 2000;6:2236-2244.
21. Ma MK, Zamboni WC, Radomski KM, et al. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clin Cancer Res 2000;6:813-819.